ReviewEuropean respiratory review : an official journal of the European Respiratory Society2017
Personalised medicine in asthma: time for action: Number 1 in the Series "Personalised medicine in respiratory diseases" Edited by Renaud Louis and Nicolas Roche.
Review in European respiratory review : an official journal of the European Respiratory Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Leveraging artificial intelligence for the management of preschool wheeze: A narrative review.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Review
- Unraveling the Molecular Complexity of Asthma: Insights from a Multicohort Transcriptome Study.American journal of respiratory cell and molecular biology · 2025Article
- Overall perspective of electrospun semiconductor metal oxides as high-performance gas sensor materials for NORSC advances · 2024Review
- How have we measured trial outcomes of asthma attack treatment? A systematic review.ERJ open research · 2024Article
- Metabolomics in Animal Models of Bronchial Asthma and Its Translational Importance for Clinics.International journal of molecular sciences · 2023Review
- Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.Advances in respiratory medicine · 2023Review
- [Biologics for the treatment of severe asthma: Current status report 2023].Tuberkuloz ve toraks · 2023Review
- [The profile of severe asthmatics: Results from a specialized asthma clinic].Tuberkuloz ve toraks · 2023Observational
- Leukocyte redistribution as immunological biomarker of corticosteroid resistance in severe asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022Article
- A Predictive Machine Learning Tool for Asthma Exacerbations: Results from a 12-Week, Open-Label Study Using an Electronic Multi-Dose Dry Powder Inhaler with Integrated Sensors.Journal of asthma and allergy · 2022Article
- Treatment Response Biomarkers in Asthma and COPD.Diagnostics (Basel, Switzerland) · 2021Review
- Plasma lipid biomarkers in relation to BMI, lung function, and airway inflammation in pediatric asthma.Metabolomics : Official journal of the Metabolomic Society · 2021Article
- Treatable Mechanisms in Asthma.Molecular diagnosis & therapy · 2021Article
- Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class Analysis and Association with 1-Year Outcomes.The journal of allergy and clinical immunology. In practice · 2020Article
- Review
- Dismantling the pathophysiology of asthma using imaging.European respiratory review : an official journal of the European Respiratory Society · 2019Review
- Biomarkers in asthma: state of the art.Asthma research and practice · 2018Review
- Personalised medicine: are we ready?European respiratory review : an official journal of the European Respiratory Society · 2017Article
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
Abstract
Asthma is a heterogeneous disease comprising several phenotypes driven by different pathways. To define these phenotypes or endotypes (phenotypes defined by mechanisms), an unbiased approach to clustering of various omics platforms will yield molecular phenotypes from which composite biomarkers can be obtained. Biomarkers can help differentiate between these phenotypes and pinpoint patients suitable for specific targeted therapies - the basis for personalised medicine. Biomarkers need to be linked to point-of-care biomarkers that may be measured readily in exhaled breath, blood or urine. The potential for using mobile healthcare approaches will help patient enpowerment, an essential tool for personalised medicine. Personalised medicine in asthma is not far off - it is already here, but we need more tools and implements to carry it out for the benefit of our patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.